NasdaqGS:RPRXPharmaceuticals
Royalty Pharma (RPRX) Valuation Check After 2026 Guidance Earnings Update And Ongoing Share Buybacks
Royalty Pharma’s latest earnings, guidance and buyback update
Royalty Pharma (RPRX) drew investor attention after releasing 2026 Portfolio Receipts guidance, reporting fourth quarter and full year 2025 results, and confirming progress on its ongoing share repurchase program.
See our latest analysis for Royalty Pharma.
Royalty Pharma’s latest guidance and earnings update comes after a period of stronger momentum, with a 30 day share price return of 12.38% and a 1 year total shareholder return...